Evidence map›Paper›PMID 42464708›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Glutathione-Responsive Acyl-Modifications for Targeted RNA Decaging and Prolonged Protein Synthesis.

Mary E Flood, Sathishkumar Kurusamy, Mark Berney, C Mark Smales, Elizabeth M Topp, Joanna F McGouran, Steven Ferguson

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mary E FloodRINN Pharma and Biopharma Centre, School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin, Ireland.
Sathishkumar KurusamyIndustrial Biotechnology Centre, School of Natural Sciences, University of Kent, Canterbury, UK.
Mark BerneyRINN Pharma and Biopharma Centre, National Institute for Bioprocess Research and Training, Mount Merrion, Dublin, Ireland.
C Mark SmalesRINN Pharma and Biopharma Centre, National Institute for Bioprocess Research and Training, Mount Merrion, Dublin, Ireland.
Elizabeth M ToppRINN Pharma and Biopharma Centre, National Institute for Bioprocess Research and Training, Mount Merrion, Dublin, Ireland.
Joanna F McGouranRINN Pharma and Biopharma Centre, School of Chemistry and Trinity Biomedical Sciences Institute, Trinity College Dublin, The University of Dublin, Dublin, Ireland.ORCID https://orcid.org/0000-0002-9349-2141
Steven FergusonRINN Pharma and Biopharma Centre, School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin, Ireland.ORCID https://orcid.org/0000-0002-8166-1956

Funding

Department of Health and Social Care using UK International DevelopmentEPSRC EP/Y530566/1Taighde Éireann-Research Ireland 21/FFP-A/9838Taighde Éireann-Research Ireland 23/RC/12165Taighde Éireann-Research Ireland 23RP11975Taighde Éireann-Research Ireland SFI18/EPSRC-CDT/3587
6 · The paper itself

Abstract

A series of disulfide-based, self-immolative acyl conjugates have been designed and tested for reversibly protecting the ribose 2'-hydroxy position of RNA. These modifications were found to be responsive to endogenous glutathione levels for efficient RNA recovery both in solution and cultured cells. Through this modification strategy, we achieve shielding of the biomolecule from both nuclease enzymes and translational machinery, allowing for a tunable release of RNA with improved cellular stability and minimal innate immune activation. The self-immolative RNA deprotection includes a cyclization step which exhibits differing kinetic profiles based on ring size and electronic properties. Moreover, we demonstrate sustained target protein production for both green-fluorescent protein and nanoluciferase in cell models. Both acylated mRNA models resulted in significant increases in protein expression compared to the unmodified mRNA control, with increases in protein expression of up to 600% and sustained higher protein expression of modified mRNA samples observed over 120 h in comparison to unmodified RNA. These exciting results highlight the versatility of our approach in the design of next-generation RNA-based prodrugs.

Indexed as

GlutathioneProtein BiosynthesisRNAAcylationGreen Fluorescent ProteinsHumansRNA, MessengerGlutathioneGreen Fluorescent ProteinsRNARNA, Messengeracyl‐modificationdecagingglutathione‐responsivemRNARNA

Identifiers

PMID42464708
PMCPMC13592295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.